Chimeric Antigen Receptor T-Cell Therapy: What We Expect Soon

Abstract excerpt

The treatment landscape for hematologic malignancies has changed since the recent approval of highly effective chimeric antigen receptor T-cell therapies (CAR-T). Moreover, more than 600 active trials are currently ongoing. However, early enthusiasm should be tempered since several issues are still unsolved and represent the challenges for the coming years. The lack of initial responses and early relapse are some...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to CAR-T cell therapy research